X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse STRIDES PHARMA SCIENCE with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ACTAVIS (US) - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 STRIDES PHARMA SCIENCE   ACTAVIS
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
ACTAVIS
Dec-18
STRIDES PHARMA SCIENCE/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,14713,773-   
Low Rs6429,239-   
Sales per share (Unadj.) Rs317.23,378.6-  
Earnings per share (Unadj.) Rs7.8-1,088.2-  
Cash flow per share (Unadj.) Rs25.1356.0-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.313,935.1-  
Shares outstanding (eoy) m89.50332.60-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.4 82.8%   
Avg P/E ratio x114.0-10.6 -1,078.4%  
P/CF ratio (eoy) x35.732.3 110.5%  
Price / Book Value ratio x3.30.8 395.0%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,0583,826,978 2.1%   
No. of employees `0002.516.9 14.8%   
Total wages/salary Rs m4,3410-   
Avg. sales/employee Rs Th11,325.866,492.2 17.0%   
Avg. wages/employee Rs Th1,731.40-   
Avg. net profit/employee Rs Th280.1-21,417.2 -1.3%   
INCOME DATA
Net Sales Rs m28,3941,123,719 2.5%  
Other income Rs m94121,489 4.4%   
Total revenues Rs m29,3341,145,208 2.6%   
Gross profit Rs m3,96529,447 13.5%  
Depreciation Rs m1,540480,365 0.3%   
Interest Rs m1,96264,845 3.0%   
Profit before tax Rs m1,403-494,274 -0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436126,060 -0.3%   
Tax Rs m97-6,264 -1.6%   
Profit after tax Rs m702-361,950 -0.2%  
Gross profit margin %14.02.6 532.9%  
Effective tax rate %6.91.3 547.2%   
Net profit margin %2.5-32.2 -7.7%  
BALANCE SHEET DATA
Current assets Rs m24,836460,891 5.4%   
Current liabilities Rs m18,993407,719 4.7%   
Net working cap to sales %20.64.7 434.9%  
Current ratio x1.31.1 115.7%  
Inventory Days Days7120 362.4%  
Debtors Days Days11366 171.0%  
Net fixed assets Rs m34,289127,199 27.0%   
Share capital Rs m8950-   
"Free" reserves Rs m23,6510-   
Net worth Rs m24,5464,634,815 0.5%   
Long term debt Rs m15,5131,632,086 1.0%   
Total assets Rs m65,4377,245,270 0.9%  
Interest coverage x1.7-6.6 -25.9%   
Debt to equity ratio x0.60.4 179.5%  
Sales to assets ratio x0.40.2 279.8%   
Return on assets %4.1-4.1 -99.3%  
Return on equity %2.9-7.8 -36.6%  
Return on capital %6.9-4.8 -142.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m14,9620-   
CASH FLOW
From Operations Rs m1,871401,462 0.5%  
From Investments Rs m5,826220,551 2.6%  
From Financial Activity Rs m-10,157-689,030 1.5%  
Net Cashflow Rs m-2,615-66,681 3.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.18 Rs / USD

Compare STRIDES PHARMA SCIENCE With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare STRIDES PHARMA SCIENCE With: ORCHID PHARMA LTD  IPCA LABS  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  STERLING BIOTECH  



Today's Market

Indian Indices Erase Gains; Sensex Ends 52 Points Higher(Closing)

After opening the day higher, Indian share markets witnessed negative trading activity during closing hours and ended their trading session marginally higher.

Related Views On News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top 3 Dividend Millionaire Stocks (Profit Hunter)

Aug 7, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

The Perfect Stock in the Rebirth of India (The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation (The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too (The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Smallcaps that Will Outperform in the Market Rebound (Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Aug 19, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS